Related Experiment Video

Updated: Jan 18, 2026

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.6K

Outcomes of coronary revascularization in patients with metabolic dysfunction-associated steatotic liver disease: a

Jacob J Gries1, Hafeez Ul Hassan Virk2, Zhen Wang3,4

  • 1Department of Gastroenterology, Allegheny Health Network, Pittsburgh, PA, United States.

Frontiers in Cardiovascular Medicine
|September 11, 2025
PubMed

Insights

Metabolic dysfunction-associated steatotic liver disease (MASLD) increases risks following percutaneous coronary intervention (PCI). Patients with MASLD face higher mortality and complications after PCI, requiring further research for optimal treatment strategies.

Area of Science:

  • Cardiology
  • Hepatology
  • Metabolic Diseases

Background:

  • Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly linked to cardiovascular disease.
  • MASLD may independently elevate the risk of coronary artery disease and acute coronary syndrome.
  • Revascularization interventions like PCI and CABG are common for these conditions, but MASLD's impact on outcomes is understudied.

Purpose of the Study:

  • To evaluate the impact of MASLD on the outcomes of cardiovascular revascularization interventions.
  • To synthesize current evidence on MASLD and its association with PCI and CABG outcomes.

Main Methods:

  • A comprehensive literature search was performed in PubMed/MEDLINE and Embase databases.
  • Studies published between August 2015 and August 2025 were included, using MeSH terms and keywords for MASLD and cardiovascular revascularization.
  • Six studies met the inclusion criteria, with five focusing on PCI and one on CABG.

Main Results:

  • MASLD is associated with increased in-hospital and long-term mortality after PCI.
  • Patients with MASLD may experience higher risks of cardiogenic shock, cardiac arrest, in-stent thrombosis, gastrointestinal bleeding, and mechanical ventilation post-PCI.
  • Limited data exists for CABG outcomes in MASLD patients.

Conclusions:

  • MASLD appears to be an independent risk factor for adverse outcomes following PCI.
  • Further investigation is crucial to establish optimal revascularization strategies and medical management for MASLD patients undergoing cardiovascular interventions.
  • The findings highlight the need for closer monitoring and tailored care for this patient population.
Abstract

Keywords:
MASLDcoronary diseasecoronary heart diseasecoronary revascularisationliver diseasemetabolic dysfunction-associated fatty liver disease (MASLD)

More Related Videos

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.8K
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

717

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
217
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
216
Liver Physiology01:30

Liver Physiology

The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of  70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
3.5K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
257